TACT908, also known as [2-(indolizin-1-yl)ethyl]dimethylamine (2ZEDMA), is a serotonin receptor agonist of the indolizinylethylamine family which is under development for the treatment of cluster headaches. It is a positional isomer of the tryptamine serotonergic psychedelic N,N-dimethyltryptamine (DMT) in which the indole ring has been replaced with an indolizine ring.
The drug acts as a serotonin 5-HT1B and 5-HT2A receptor agonist. Its at the serotonin 5-HT2A receptor is 52nM ( ≈ 30% of that of serotonin) and its at the serotonin 5-HT1B receptor is 143nM. TACT908 is said to be a non-hallucinogenic serotonin 5-HT2A receptor agonist. It showed little or no activity at 45other screened targets, including the serotonin 5-HT1A, 5-HT2B, and 5-HT3 receptors as well as the monoamine transporters (MATs). Other serotonin receptors besides the preceding, such as the serotonin 5-HT2C receptor, were not assessed. The drug was a weak monoamine oxidase inhibitor (MAOI), specifically of monoamine oxidase A (MAO-A) ( = 7,252nM).
TACT908 is under development by Tactogen. It was patented by Matthew Baggott of Tactogen in 2023. As of January 2025, the drug is in preclinical research for cluster headaches.
The α-methyl and N-desmethyl analogue of TACT908, 1ZP2MA ([1-(indolizin-1-yl)propan-2-yl](methyl)amine or 1-(indolizin-1-yl)-N-methylpropan-2-amine), has also been characterized and described. It is the indolizine analogue of α,N-dimethyltryptamine (α,N-DMT or N-methyl-). 1ZP2MA was found to be a potent dopamine releasing agent, with an of 62nM.
See also Indolizinylethylamine Substituted tryptamine § Related compounds List of investigational hallucinogens and entactogens Non-hallucinogenic 5-HT2A receptor agonist N,N-Dimethylisotryptamine (isoDMT) 1Z2MAP1O C-DMT S-DMT TACT411 Rizatriptan TACT833
References
External links TACT908 (2ZEDMA) - Isomer Design